Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients

World Journal of Gastroenterology

Volumn 19, Issue 28, 2013, Pages 4568-4575

  Shen, Yan Ying ^a   Lu, Ya Chao ^a,b   Shen, Dan Ping ^a   Liu, Yuan Jie ^a,b   Su, Xin Ying ^a,b   Zhu, Guan Shan ^a,b   Yin, Xiao Lu ^a,b   Ni, Xing Zhi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Innovation Center China   (China)

Author keywords

Fibroblast growth factor receptor 4; Gastric cancer; Genetic susceptibility; Gly388Arg; Single nucleotide polymorphism

Indexed keywords

ARGININE; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLYCINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER;

EID: 84880768178     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i28.4568     Document Type: Article

References (36)

1. Fenoglio-Preiser C, Carneiro F, Correa P, Guilford P, Lambert R, Megraud F, Munoz N, Powell SM, Rugge M, Sasako M, Stolte M, Watanabe H. Gastric carcinoma. In: Hamilton SR, Aaltonen LA, editor. World Health Organization Classification of Tumors, Pathology and genetics of tumors of the digestive system. Lyon: LARC Press, 2000: 39-40
2. Zagouri F, Papadimitriou CA, Dimopoulos MA, Pectasides D. Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review. Cancer Treat Rev 2011; 37: 599-610 [PMID: 21676549 DOI: 10.1016/j.ctrv.2011.03.007]
3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/s0140-6736(10)61121-x]
4. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529 [PMID: 18441328 DOI: 10.1093/annonc/mdn169]
5. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 273-278 [PMID: 15668283 DOI: 10.1093/annonc/ mdi064]
6. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805 [PMID: 18422971 DOI: 10.1111/j.1365-2559.2008.03028.x]
7. Takaishi S, Sawada M, Morita Y, Seno H, Fukuzawa H, Chiba T. Identification of a novel alternative splicing of human FGF receptor 4: soluble-form splice variant expressed in human gastrointestinal epithelial cells. Biochem Biophys Res Commun 2000; 267: 658-662 [PMID: 10631118 DOI: 10.1006/bbrc.1999.2010]
8. Shin EY, Lee BH, Yang JH, Shin KS, Lee GK, Yun HY, Song YJ, Park SC, Kim EG. Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer. J Cancer Res Clin Oncol 2000; 126: 519-528 [PMID: 11003564 DOI: 10.1007/s004320000128]
9. Ye YW, Zhang X, Zhou Y, Wu J, Zhao C, Yuan L, Wang G, Du C, Wang C, Shi Y. The correlations between the expression of FGFR4 protein and clinicopathological parameters as well as prognosis of gastric cancer patients. J Surg Oncol 2012; 106: 872-879 [PMID: 22585711 DOI: 10.1002/jso.23153]
10. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Müller S, Gärtner S, Sures I, Wang H, Imyanitov E, Häring HU, Knayzev P, Iacobelli S, Höfler H, Ullrich A. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002; 62: 840-847 [PMID: 11830541]
11. Spinola M, Leoni VP, Tanuma J, Pettinicchio A, Frattini M, Signoroni S, Agresti R, Giovanazzi R, Pilotti S, Bertario L, Ravagnani F, Dragani TA. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 2005; 14: 415-419 [PMID: 16012724]
12. Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U, Dragani TA. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005; 23: 7307-7311 [PMID: 16061909 DOI: 10.1200/JCO.2005.17.350]
13. FitzGerald LM, Karlins E, Karyadi DM, Kwon EM, Koopmeiners JS, Stanford JL, Ostrander EA. Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer Prostatic Dis 2009; 12: 192-197 [PMID: 18762813 DOI: 10.1038/pcan.2008.46]
14. Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S, Horikawa Y, Tsuruta H, Obara T, Saito M, Satoh S, Ogawa O, Habuchi T. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer 2008; 123: 2574-2579 [PMID: 18756523 DOI: 10.1002/ijc.23578]
15. Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A, Shimizu K, Inoue H. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 2003; 98: 2245-2250 [PMID: 14601095 DOI: 10.1002/ cncr.11778]
16. Streit S, Mestel DS, Schmidt M, Ullrich A, Berking C. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006; 94: 1879-1886 [PMID: 16721364 DOI: 10.1038/ sj.bjc.6603181]
17. da Costa Andrade VC, Parise O, Hors CP, de Melo Martins PC, Silva AP, Garicochea B. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007; 82: 53-57 [PMID: 17084840 DOI: 10.1016/j.yexmp.2006.05.003]
18. Sasaki H, Okuda K, Kawano O, Yukiue H, Yano M, Fujii Y. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer. Oncol Rep 2008; 20: 1125-1130 [PMID: 18949411 DOI: 10.3892/or_00000119]
19. Tanuma J, Izumo T, Hirano M, Oyazato Y, Hori F, Umemura E, Shisa H, Hiai H, Kitano M. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. Oncol Rep 2010; 23: 739-744 [PMID: 20127014 DOI: 10.3892/or_00000692]
20. Jézéquel P, Campion L, Joalland MP, Millour M, Dravet F, Classe JM, Delecroix V, Deporte R, Fumoleau P, Ricolleau G. G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 2004; 90: 189-193 [PMID: 14710228 DOI: 10.1038/sj.bjc.6601450]
21. Yang YC, Lu ML, Rao JY, Wallerand H, Cai L, Cao W, Pantuck A, Dalbagni G, Reuter V, Figlin RA, Belldegrun A, Cordon-Cardo C, Zhang ZF. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer 2006; 95: 1455-1458 [PMID: 17088904 DOI: 10.1038/sj.bjc.6603456]
22. Mawrin C, Kirches E, Diete S, Wiedemann FR, Schneider T, Firsching R, Kropf S, Bogerts B, Vorwerk CK, Krüger S, Dietzmann K. Analysis of a single nucleotide polymorphism in codon 388 of the FGFR4 gene in malignant gliomas. Cancer Lett 2006; 239: 239-245 [PMID: 16198476 DOI: 10.1016/ j.canlet.2005.08.013]
23. Matakidou A, El Galta R, Rudd MF, Webb EL, Bridle H, Eisen T, Houlston RS. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer 2007; 96: 1904-1907 [PMID: 17519899 DOI: 10.1038/sj.bjc.6603816]
24. Naidu R, Har YC, Taib NA. Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development. Oncol Res 2009; 18: 65-71 [PMID: 20066896 DOI: 10.3727/096504009789954609]
25. Xu B, Tong N, Chen SQ, Hua LX, Wang ZJ, Zhang ZD, Chen M. FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls. BMC Cancer 2011; 11: 84 [PMID: 21349172 DOI: 10.1186/1471-2407-11-84]
26. Ye Y, Shi Y, Zhou Y, Du C, Wang C, Zhan H, Zheng B, Cao X, Sun MH, Fu H. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression. Ann Surg Oncol 2010; 17: 3354-3361 [PMID: 20844967 DOI: 10.1245/s10434-010-1323-6]
27. Chen Q, Li WJ, Wan YY, Yu CD, Li WG. Fibroblast growth factor receptor 4 Gly388Arg polymorphism associated with severity of gallstone disease in a Chinese population. Genet Mol Res 2012; 11: 548-555 [PMID: 22535390 DOI: 10.4238/2012.March.8.3]
28. Zhu Q, Liu T. Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study. Mol Biol Rep 2012; 39: 8679-8685 [PMID: 22696188 DOI: 10.1007/ s11033-012-1723-8]
29. Ma L, Zhang H, Han C, Tong D, Zhang M, Yao Y, Luo Y, Liu X. Fibroblast growth factor receptor 4 polymorphisms and susceptibility to coronary artery disease. DNA Cell Biol 2012; 31: 1064-1069 [PMID: 22313031 DOI: 10.1089/dna.2011.1552]
30. Yang Y, Zhou Y, Lu M, An Y, Li R, Chen Y, Lu DR, Jin L, Zhou WP, Qian J, Wang HY. Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma. Mol Carcinog 2012; 51: 515-521 [PMID: 21656577 DOI: 10.1002/mc.20805]
31. Xu W, Li Y, Wang X, Chen B, Wang Y, Liu S, Xu J, Zhao W, Wu J. FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects. Eur J Cancer 2010; 46: 3332-3338 [PMID: 20638838 DOI: 10.1016/ j.ejca.2010.06.017]
32. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A, Harbeck N. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006; 24: 3747-3755 [PMID: 16822847 DOI: 10.1200/JCO.2005.04.8587]
33. Farnebo L, Jedlinski A, Ansell A, Vainikka L, Thunell LK, Grénman R, Johansson AC, Roberg K. Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines. Int J Mol Med 2009; 24: 549-556 [PMID: 19724896 DOI: 10.3892/ijmm_00000264]
34. Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alphafetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009; 50: 118-127 [PMID: 19008009 DOI: 10.1016/j.jhep.2008.08.015]
35. Ho CK, Anwar S, Nanda J, Habib FK. FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men. Prostate Cancer Prostatic Dis 2010; 13: 94-96 [PMID: 19918264 DOI: 10.1038/pcan.2009.49]
36. Wang J, Yu W, Cai Y, Ren C, Ittmann MM. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 2008; 10: 847-856 [PMID: 18670643 DOI: 10.1593/neo.08450]